Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMGSFV)

• Drug Name: PF-06700841 Drug Info
• Synonyms: BUWBRTXGQRBBHG-RUXDESIVSA-N; 2140301-96-6; PF-06700841 free base; EX-A2762; 1883299-62-4; ((S)-2,2-difluorocyclopropyl)(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Phase 2	[1]
Plaque psoriasis	EA90.0	Phase 2	[1]
Psoriasis vulgaris	EA90	Phase 1	[2]

• Cross-matching ID:
  PubChem CID: 118878093
  CAS Number: CAS 1883299-62-4
  TTD Drug ID: DMMGSFV

Molecule-Related Drug Atlas

Drug(s) Targeting Janus kinase 1 (JAK-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Baricitinib	DM4ONW5	Rheumatoid arthritis	FA20	Approved	[3]
Ruxolitinib	DM7Q98D	Essential thrombocythemia	3B63.1Z	Approved	[4]
Upadacitinib	DM32B5U	Rheumatoid arthritis	FA20	Approved	[5]
ASP-015K	DMZ1UOI	Psoriasis vulgaris	EA90	Phase 3	[6]
SHR0302	DMUL8ZT	Ulcerative colitis	DD71	Phase 3	[7]
Cerdulatinib	DMSCR2H	B-cell lymphoma	2A86	Phase 2	[1]
CTP-543	DM3SYOK	Alopecia	ED70	Phase 2	[2]
INCB039110	DMD9RV3	Malignant neoplasm	2A00-2F9Z	Phase 2	[6]
ATI-501	DMTY6OF	Alopecia	ED70	Phase 2	[8]
ATI-502	DM8NODR	Alopecia	ED70	Phase 2	[9]

Drug(s) Targeting TYK2 tyrosine kinase (TYK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Deucravacitinib	DMAR1YS	Plaque psoriasis	EA90.0	Approved	[1]
PF-06826647	DM5H8V1	Plaque psoriasis	EA90.0	Phase 2	[1]
PF-06826647	DM5H8V1	Plaque psoriasis	EA90.0	Phase 2	[10]
NDI-034858	DM2FJE7	Psoriatic arthritis	FA21	Phase 2	[11]
Pyrazolo[4,3-c]pyridine derivative 2	DMCDFLQ	N. A.	N. A.	Patented	[12]
PMID27774824-Compound-Figure9Example2down	DMXAV42	N. A.	N. A.	Patented	[12]
Aminotriazolopyridine derivative 1	DMW2LZ0	N. A.	N. A.	Patented	[12]
Imidazo[4,5-c]pyridine derivative 2	DMFDRJT	N. A.	N. A.	Patented	[12]
PMID27774824-Compound-Figure11Example1up	DMH1W8F	N. A.	N. A.	Patented	[12]
Imidazo[4,5-c]pyridine derivative 1	DM4KBZQ	N. A.	N. A.	Patented	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Janus kinase 1 (JAK-1)	TT6DM01	JAK1_HUMAN	Inhibitor	[1]
TYK2 tyrosine kinase (TYK2)	TTBYWP2	TYK2_HUMAN	Inhibitor	[1]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
• [4] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2047).
• [7] Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial. Am J Clin Dermatol. 2021 Nov;22(6):877-889.
• [8] Clinical pipeline report, company report or official report of Aclaris Therapeutics.
• [9] ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health.
• [10] Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases. J Med Chem. 2020 Nov 25;63(22):13561-13577.
• [11] Clinical pipeline report, company report or official report of Nimbus Therapeutics
• [12] Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.